Pesquisar
Lantheus Holdings Inc
LNTHAdicionar à lista de desejos
109.010USD
+4.160+3.97%
Fechamento 06/25, 16:00（ET）Cotações atrasadas em 15 min
7.09BValor de mercado
25.78P/L TTM
Mais detalhes de Lantheus Holdings Inc Empresa
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Informações de Lantheus Holdings Inc
Código da empresaLNTH
Nome da EmpresaLantheus Holdings Inc
Data de listagemJun 25, 2015
CEOMarkison (Brian A)
Número de funcionários808
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço331 Treble Cove Road
CidadeNORTH BILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01862
Telefone19786718001
Sitehttps://www.lantheus.com/
Código da empresaLNTH
Data de listagemJun 25, 2015
CEOMarkison (Brian A)
Executivos da empresa Lantheus Holdings Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
4.70K
+88.02%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Perguntas frequentes
Quem são os cinco principais acionistas de Lantheus Holdings Inc?
Os cinco principais acionistas de Lantheus Holdings Inc são: Ms. Mary Anne Heino
Quantas instituições possuem ações da Lantheus Holdings Inc (LNTH)?
Em 2026Q1, 1043 instituições possuíam ações da Lantheus Holdings Inc, com valor de mercado aproximado de 77.80M, representando 119.49% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -5936003.00.
